Blinatumomab after stem cell transplant for high-risk B-ALL
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests whether the drug blinatumomab, given after a stem cell transplant, can help prevent high-risk B-ALL from coming back. It is for people who have already had a transplant and meet certain health criteria.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 16 and 65 years old.
- You have B-cell acute lymphoblastic leukemia (B-ALL) that tests positive for a marker called CD19.
- Your leukemia is considered high-risk.
- You have a suitable stem cell donor available (like a family member or matched unrelated donor).
- Your vital organs (like heart, liver, kidneys) are working well enough to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a targeted drug, blinatumomab, can help prevent leukemia from coming back after a stem cell transplant. It is for people with high-risk B-cell acute lymphoblastic leukemia who have achieved remission but are at high risk of relapse.
This trial tests giving a drug called blinatumomab before a stem cell transplant for people with high-risk B-cell acute lymphoblastic leukemia (B-ALL) that is in remission and has no detectable cancer cells. The goal is to see if this extra treatment helps prevent the leukemia from coming back after transplant.
This trial tests blinatumomab, an immune therapy, in young people with B-cell acute lymphoblastic leukemia (B-ALL) after their transplant or when they are getting ready for transplant. The goal is to lower the chance of the leukemia coming back by targeting remaining leukemia cells.
This trial tests the drug blinatumomab for people whose B-cell acute lymphoblastic leukemia (B-ALL) has come back after a stem cell transplant. The goal is to see if blinatumomab can safely treat the relapse.
This trial tests a drug called blinatumomab for people with B-ALL whose leukemia has come back at a very low level (detected only by sensitive testing) after a stem cell transplant. The goal is to see if blinatumomab can clear these remaining leukemia cells and prevent a full relapse.
This trial tests whether giving two drugs—blinatumomab (an immunotherapy) and donor lymphocyte infusions (white blood cells from your donor)—can help prevent leukemia from coming back after a stem cell transplant for high-risk B-ALL. It is for people who are in remission with no sign of leukemia cells.
Hear when a new High Risk Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.